Novo Nordisk hasn't yet released the full trial results, but the study may be compelling enough to get insurance companies to provide coverage for the expensive medication, said Dr. Shauna Levy, a specialist in obesity medicine and the medical director of the Tulane Bariatric Center in New Orleans.
Many people who take Wegovy have had trouble getting insurance to cover the weekly injections, which cost more than $1,300“Twenty percent is huge,” Levy said. “All of this narrative about people just wanting this for cosmetic reasons, I think, to some degree, has overshadowed all of the health benefits we can get from this medication.”in the United StatesThe evidence that Wegovy can reduce heart risks along with weight loss may change some views that it's a vanity drug, said Dr.
The individuals had overweight or obesity, as well as existing cardiovascular disease, but no previous history of diabetes. Novo Nordisk said the drug appeared to be safe and well tolerated, in line with what has been seen in previous clinical trials. The results were announced in a news release and have not yet been reviewed by outside scientists. The company didn't say how much weight the participants lost. It's also unclear whether the cardiovascular benefits were a result of the weight loss or some other mechanism in the drug.More news on weight-loss drugs
Россия Последние новости, Россия Последние новости
Similar News:Вы также можете прочитать подобные новости, которые мы собрали из других источников новостей
Источник: NBCNews - 🏆 10. / 86 Прочитайте больше »